Skip to main content
Fig. 2 | BMC Nephrology

Fig. 2

From: Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study

Fig. 2

Alteration of ΔeGFR due to febuxostat therapy. The changes of eGFR (ΔeGFR) after febuxostat administration (baseline, 3 and 6 months after treatment initiation). a All patients (n = 178). b The ΔeGFR was analyzed by dividing patients into mean serum uric acid level (mUA) < 6.0 mg/dl (blue line, n = 78) vs. mUA ≥ 6.0 mg/dl (red line, n = 100) groups. ΔeGFR represent the mean ± SE. ΔeGFR was defined as the difference obtained by subtracting baseline eGFR from post-treatment eGFR. **p < 0.01; compared with baseline UA level in each group (Wilcoxon signed-rank test). # p < 0.05, ## p < 0.01; comparison between mUA < 6.0 and mUA ≥ 6.0 mg/dl groups (Mann-Whitney U test)

Back to article page
\